Mapping the ATMP capacities in Europe: PRECISEU launches strategic initiative

Clust-ER Health, as a partner in the EU-funded PRECISEU project, is contributing to a major European initiative to build the most comprehensive map yet of Europe’s capabilities in Advanced Therapy Medicinal Products (ATMPs). This effort aims to strengthen Europe’s readiness to deliver advanced therapies through a more coordinated, data-driven, and equitable health innovation ecosystem.

Building a more coordinated and efficient European ATMP ecosystem

ATMPs (including cell and gene therapies, and tissue-engineered products) constitute a rapidly evolving and promising sector in biomedical science. However, their integration into healthcare systems across Europe remains uneven. Infrastructure gaps, regulatory variability, and disparities in access to expertise all contribute to inconsistent availability and implementation of these innovative therapies.

The initiative, led by the European infrastructure for translational medicine EATRIS, aims to bring clarity to the fragmented ATMP landscape by identifying where the expertise, infrastructure, and innovation potential truly lie. From academic labs and hospitals to biotech startups and manufacturing facilities — every player matters.

We are inviting all stakeholders in the ATMP ecosystem to take part in the pan-European survey that will inform this strategic mapping effort, including:

• Academic and translational research centers
• GMP and Pre-GMP manufacturing and processing facilities
• Clinical trial sites and hospitals
• National regulatory frameworks and logistics infrastructure

By understanding who is doing what — and where — we can build smarter networks, scale best practices, and ultimately ensure that every patient in Europe has access to advanced therapies. This is your opportunity to shape the future of European precision medicine!

The first data collection phase of the ATMPs map will close on 30 May 2025.

Driving Strategic Planning and Collaboration

The results of this mapping will support more informed and strategic decision-making at both national and European levels. Specifically, it will help:

• Guide public and private investments
• Strengthen clinical and industrial capacity building in under-served regions
• Facilitate efficient patient referral pathways for highly specialised treatments
• Optimise site selection for clinical trials and manufacturing
• Increase synergies and cooperation between academia, industry, and healthcare providers.

Furthermore, the initiative will support improved cross-border collaboration and knowledge exchange as well as greater alignment in regulatory and logistical processes, key factors for delivering ATMPs efficiently and at scale.

Emilia-Romagna’s Role in a European Vision

With the active participation of Clust-ER Health, ART-ER, and the Emilia-Romagna Region, this initiative underscores the region’s commitment to driving innovation in life sciences and healthcare. Our involvement in PRECISEU reflects a broader vision: to place regional excellence at the heart of European strategies for precision medicine and next-generation therapies.

This mapping initiative is not just a snapshot of current capacities, it is expected to serve as a strategic tool for long-term planning, helping build a stronger, more connected ecosystem for advanced therapies. By identifying key strengths and unmet needs, we can support policies and partnerships that will improve access to ATMPs for all patients, regardless of geography.

To know more about the PRECISE project, visit the official website.

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Innovation Council and SMEs Executive Agency (EISMEA). Neither the European Union nor the granting authority can be held responsible for them.